Achillion Pharma (ACHN) Reports Q3 Loss of $0.15

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. DAL
9. TMUS
10. VZ

Go back to Achillion Pharma (ACHN) Reports Q3 Loss of $0.15

Leerink Maintains Achillion Pharma (ACHN) at 'Market Perform'; Says MAD Study Questions Raised

November 3, 2016 11:55 AM EDT

Leerink affirms Achillion Pharma (NASDAQ: ACHN) at Market Perform following Q3 results and update issued earlier Thursday.

The firm commented today: We believe today's stock weakness is related to caution due to ACHN's disclosure of two cases of liver enzyme elevations in the ongoing multiple ascending dose (MAD) Phase I study of ACH-4471. This update was mentioned... More

Achillion Pharmaceuticals (ACHN) Sell Rating Reiterated at Chardan Capital Markets Amid ACH-4471 Risks

November 3, 2016 11:16 AM EDT

Chardan Capital Markets analyst Madhu Kumar reiterated a Sell rating and $5 price target on Achillion Pharmaceuticals (NASDAQ: ACHN) saying ACH-4471 liver signals and developmental delays pose risks.

Kumar commented, "This morning, Achillion Pharmaceuticals (Sell) announced 3Q16 earnings results and updates on clinical... More

Achillion Pharma (ACHN) Announces Two Side Effects Observed in MAD Study

November 3, 2016 10:20 AM EDT

Achillion Pharma (NASDAQ: ACHN) posted the following with its Q3 press release on Thursday:

Phase I Clinical... More